{"success":true,"data":{"pressRelease":{"id":"164805","rtpr_id":"nGNX7zlwmj-20261008","ticker":"NBP","exchange":"NASDAQ","all_tickers":["NBP"],"title":"NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026","author":"Globe Newswire","published_at":"2026-10-08T20:05:00.291Z","article_body":"ROCKVILLE, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences\n(NASDAQ: NBP) today announced that updated results from the Phase 1b\ncombination study of givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific\nantibody, in combination with nivolumab and chemotherapy (mFOLFOX6) in\nparticipants with previously untreated, HER2-negative, CLDN18.2-positive, and\nPD-L1-positive locally advanced, unresectable, or metastatic gastroesophageal\nadenocarcinoma (GEA), will be presented at the European Society for Medical\nOncology (ESMO) Congress 2026. ESMO Congress 2026 is scheduled to take place\nOctober 23-27, 2026, in Madrid, Spain.\n\n“Patients with metastatic gastroesophageal adenocarcinoma continue to need\nmore effective treatment options, particularly those whose tumors express\nlower levels of CLDN18.2,” said Phillip Dennis, MD, PhD, Chief Medical\nOfficer of NovaBridge. “Givastomig is designed to amplify T-cell activity\nwhere CLDN18.2 is expressed. The data we plan to share at ESMO will provide a\nmore mature view of the safety, efficacy and durability observed to date in\ncombination with nivolumab and chemotherapy. These findings further strengthen\nour confidence in the program as we advance toward registrational development\nin first-line metastatic gastroesophageal adenocarcinoma.”\n\nPresentation Details\nTitle: Expanded Safety and Efficacy of Givastomig, a Claudin 18.2/4-1BB\nBispecific Antibody, in Combination with Nivolumab and mFOLFOX in 1L\nMetastatic Gastroesophageal Carcinoma (mGEC)\nPresentation Number: 2945P\nPresenter: Samuel J. Klempner, MD, Associate Professor of Medicine at\nMassachusetts General Hospital\nDate: Sunday, October 25, 2026\nTime: 12:00 p.m. - 12:45 p.m. CET\nLocation: Poster Area, Hall 5\n\nAbout Givastomig\nGivastomig (TJ033721 / ABL111), a potential first-in-class Conditional T-cell\nEngager and Immune Amplifier (CTIA), is a Claudin 18.2 × 4-1BB bispecific\nantibody. Givastomig conditionally activates T cells via the 4-1BB signaling\npathway in the tumor microenvironment where Claudin 18.2 is expressed.\nGivastomig is being developed for potential treatment of gastroesophageal\nadenocarcinoma, its current lead indication. Givastomig also has potential\napplicability across other Claudin 18.2+ gastrointestinal malignancies\nincluding biliary tract cancer and pancreatic ductal adenocarcinoma.\n\nGivastomig is being evaluated in a global, randomized Phase 2 study\n(NCT07432295), following positive topline results from a Phase 1b multicenter,\nopen-label study in first-line metastatic gastroesophageal adenocarcinoma. The\nU.S. Food and Drug Administration (FDA) has granted Fast Track Designation to\ngivastomig for the treatment of previously untreated HER2-negative advanced or\nmetastatic gastroesophageal adenocarcinoma in combination with nivolumab and\nchemotherapy.\n\nAbout NovaBridge\nNovaBridge Biosciences (NASDAQ: NBP) is a global biotechnology company\nadvancing a portfolio of therapeutic programs in oncology and ophthalmology.\nThe Company identifies differentiated therapeutic opportunities, generates\nvalue-defining clinical evidence, and applies the development, financing, and\npartnering strategy best suited to each program.\n\nNovaBridge's portfolio is led by givastomig, a Claudin 18.2 × 4-1BB\nbispecific antibody being developed for the potential treatment of\ngastrointestinal malignancies, and VIS-101, a tetravalent VEGF-A × ANG-2\npeptibody being developed for the potential treatment of neovascular retinal\ndiseases.\n\nThe Company's objective is to build a sustainable biotechnology company by\nrepeatedly identifying differentiated innovation, advancing it efficiently,\nand bringing novel therapies to patients through the development, partnering,\nor commercialization path best suited to each opportunity.\n\nFor more information, please visit www.novabridge.com and follow us on\nLinkedIn.\n\nForward Looking Statements\nThis announcement contains forward-looking statements. These statements are\nmade under the “safe harbor” provisions of the U.S. Private Securities\nLitigation Reform Act of 1995. These forward-looking statements can be\nidentified by terminology such as “will,” “expects,” “believes,”\n“designed to,” “anticipates,” “future,” “intends,”\n“plans,” “potential,” “estimates,” “confident,” “look\nforward to,” and similar terms or the negative thereof. NovaBridge may also\nmake written or oral forward-looking statements in its periodic reports to the\nU.S. Securities and Exchange Commission (the SEC), in its annual report to\nshareholders, in press releases and other written materials and in oral\nstatements made by its officers, directors or employees to third parties.\nStatements that are not historical facts, including statements about the\nCompany’s beliefs and expectations, are forward-looking statements.\nForward-looking statements in this press release include, without limitation,\nstatements regarding the strategy, clinical development, regulatory strategy\nand designations, including Fast Track Designation, plans, results, safety and\nefficacy for givastomig, VIS-101 and its other drug candidates; the strategic\nand clinical development of NovaBridge’s drug candidates, including\ngivastomig, VIS-101, ragistomig, and uliledlimab; anticipated clinical\nmilestones and results, and related timing. Forward-looking statements involve\ninherent risks and uncertainties that may cause actual results to differ\nmaterially from those contained in these forward-looking statements, including\nbut not limited to the following: the Company’s ability to demonstrate the\nsafety and efficacy of its drug candidates; the clinical results for its drug\ncandidates, which may or may not support further development or New Drug\nApplication/Biologics License Application (NDA/BLA) approval or eligibility\nfor accelerated approval pathway or receipt of accelerated approval; the\ncontent and timing of decisions made by the relevant regulatory authorities,\nincluding the FDA, regarding regulatory approval of the Company’s drug\ncandidates; the Company’s ability to achieve commercial success for its drug\ncandidates, if approved; the Company’s ability to obtain and maintain\nprotection of intellectual property for its technology and drugs; the\nCompany’s reliance on third parties to conduct drug development,\nmanufacturing and other services; the Company’s limited operating history\nand the Company’s ability to obtain additional funding for operations and to\ncomplete the development and commercialization of its drug candidates; the\nimpact of macroeconomic conditions, including inflation, tariffs, volatile\ninterest rates, regulatory uncertainty, potential government shutdowns,\nvolatility in the capital markets, and regional and other global events,\nincluding ongoing armed conflicts in different regions of the world; and those\nrisks more fully discussed in the “Risk Factors” section in the\nCompany’s annual report on Form 20-F filed with the SEC on April 7, 2026,\nand amended on June 16, 2026, as well as the discussions of potential risks,\nuncertainties, and other important factors in the Company’s subsequent\nfilings with the SEC. All forward-looking statements are based on information\ncurrently available to the Company. The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, whether as a result\nof new information, future events, or otherwise, except as may be required by\nlaw.\n\nNovaBridge Investor & Media Contacts\n\nInvestors:\nBill Begien, SVP, Investor Relations\n+1-240-745-6330\nbill.begien@novabridge.com \nIR@novabridge.com \n\nMedia Inquiries:\nEric Van Zanten, VP, Communications\n+1-610-529-6219\neric.vanzanten@novabridge.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0ea9f005-c7f7-4272-a3ac-cbf4ea4aef15)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7zlwmj-20261008","title":"NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026","author":"Globe Newswire","ticker":"NBP","created":"2026-10-08T20:05:00.291Z","tickers":["NBP"],"exchange":"NASDAQ","article_body":"ROCKVILLE, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences\n(NASDAQ: NBP) today announced that updated results from the Phase 1b\ncombination study of givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific\nantibody, in combination with nivolumab and chemotherapy (mFOLFOX6) in\nparticipants with previously untreated, HER2-negative, CLDN18.2-positive, and\nPD-L1-positive locally advanced, unresectable, or metastatic gastroesophageal\nadenocarcinoma (GEA), will be presented at the European Society for Medical\nOncology (ESMO) Congress 2026. ESMO Congress 2026 is scheduled to take place\nOctober 23-27, 2026, in Madrid, Spain.\n\n“Patients with metastatic gastroesophageal adenocarcinoma continue to need\nmore effective treatment options, particularly those whose tumors express\nlower levels of CLDN18.2,” said Phillip Dennis, MD, PhD, Chief Medical\nOfficer of NovaBridge. “Givastomig is designed to amplify T-cell activity\nwhere CLDN18.2 is expressed. The data we plan to share at ESMO will provide a\nmore mature view of the safety, efficacy and durability observed to date in\ncombination with nivolumab and chemotherapy. These findings further strengthen\nour confidence in the program as we advance toward registrational development\nin first-line metastatic gastroesophageal adenocarcinoma.”\n\nPresentation Details\nTitle: Expanded Safety and Efficacy of Givastomig, a Claudin 18.2/4-1BB\nBispecific Antibody, in Combination with Nivolumab and mFOLFOX in 1L\nMetastatic Gastroesophageal Carcinoma (mGEC)\nPresentation Number: 2945P\nPresenter: Samuel J. Klempner, MD, Associate Professor of Medicine at\nMassachusetts General Hospital\nDate: Sunday, October 25, 2026\nTime: 12:00 p.m. - 12:45 p.m. CET\nLocation: Poster Area, Hall 5\n\nAbout Givastomig\nGivastomig (TJ033721 / ABL111), a potential first-in-class Conditional T-cell\nEngager and Immune Amplifier (CTIA), is a Claudin 18.2 × 4-1BB bispecific\nantibody. Givastomig conditionally activates T cells via the 4-1BB signaling\npathway in the tumor microenvironment where Claudin 18.2 is expressed.\nGivastomig is being developed for potential treatment of gastroesophageal\nadenocarcinoma, its current lead indication. Givastomig also has potential\napplicability across other Claudin 18.2+ gastrointestinal malignancies\nincluding biliary tract cancer and pancreatic ductal adenocarcinoma.\n\nGivastomig is being evaluated in a global, randomized Phase 2 study\n(NCT07432295), following positive topline results from a Phase 1b multicenter,\nopen-label study in first-line metastatic gastroesophageal adenocarcinoma. The\nU.S. Food and Drug Administration (FDA) has granted Fast Track Designation to\ngivastomig for the treatment of previously untreated HER2-negative advanced or\nmetastatic gastroesophageal adenocarcinoma in combination with nivolumab and\nchemotherapy.\n\nAbout NovaBridge\nNovaBridge Biosciences (NASDAQ: NBP) is a global biotechnology company\nadvancing a portfolio of therapeutic programs in oncology and ophthalmology.\nThe Company identifies differentiated therapeutic opportunities, generates\nvalue-defining clinical evidence, and applies the development, financing, and\npartnering strategy best suited to each program.\n\nNovaBridge's portfolio is led by givastomig, a Claudin 18.2 × 4-1BB\nbispecific antibody being developed for the potential treatment of\ngastrointestinal malignancies, and VIS-101, a tetravalent VEGF-A × ANG-2\npeptibody being developed for the potential treatment of neovascular retinal\ndiseases.\n\nThe Company's objective is to build a sustainable biotechnology company by\nrepeatedly identifying differentiated innovation, advancing it efficiently,\nand bringing novel therapies to patients through the development, partnering,\nor commercialization path best suited to each opportunity.\n\nFor more information, please visit www.novabridge.com and follow us on\nLinkedIn.\n\nForward Looking Statements\nThis announcement contains forward-looking statements. These statements are\nmade under the “safe harbor” provisions of the U.S. Private Securities\nLitigation Reform Act of 1995. These forward-looking statements can be\nidentified by terminology such as “will,” “expects,” “believes,”\n“designed to,” “anticipates,” “future,” “intends,”\n“plans,” “potential,” “estimates,” “confident,” “look\nforward to,” and similar terms or the negative thereof. NovaBridge may also\nmake written or oral forward-looking statements in its periodic reports to the\nU.S. Securities and Exchange Commission (the SEC), in its annual report to\nshareholders, in press releases and other written materials and in oral\nstatements made by its officers, directors or employees to third parties.\nStatements that are not historical facts, including statements about the\nCompany’s beliefs and expectations, are forward-looking statements.\nForward-looking statements in this press release include, without limitation,\nstatements regarding the strategy, clinical development, regulatory strategy\nand designations, including Fast Track Designation, plans, results, safety and\nefficacy for givastomig, VIS-101 and its other drug candidates; the strategic\nand clinical development of NovaBridge’s drug candidates, including\ngivastomig, VIS-101, ragistomig, and uliledlimab; anticipated clinical\nmilestones and results, and related timing. Forward-looking statements involve\ninherent risks and uncertainties that may cause actual results to differ\nmaterially from those contained in these forward-looking statements, including\nbut not limited to the following: the Company’s ability to demonstrate the\nsafety and efficacy of its drug candidates; the clinical results for its drug\ncandidates, which may or may not support further development or New Drug\nApplication/Biologics License Application (NDA/BLA) approval or eligibility\nfor accelerated approval pathway or receipt of accelerated approval; the\ncontent and timing of decisions made by the relevant regulatory authorities,\nincluding the FDA, regarding regulatory approval of the Company’s drug\ncandidates; the Company’s ability to achieve commercial success for its drug\ncandidates, if approved; the Company’s ability to obtain and maintain\nprotection of intellectual property for its technology and drugs; the\nCompany’s reliance on third parties to conduct drug development,\nmanufacturing and other services; the Company’s limited operating history\nand the Company’s ability to obtain additional funding for operations and to\ncomplete the development and commercialization of its drug candidates; the\nimpact of macroeconomic conditions, including inflation, tariffs, volatile\ninterest rates, regulatory uncertainty, potential government shutdowns,\nvolatility in the capital markets, and regional and other global events,\nincluding ongoing armed conflicts in different regions of the world; and those\nrisks more fully discussed in the “Risk Factors” section in the\nCompany’s annual report on Form 20-F filed with the SEC on April 7, 2026,\nand amended on June 16, 2026, as well as the discussions of potential risks,\nuncertainties, and other important factors in the Company’s subsequent\nfilings with the SEC. All forward-looking statements are based on information\ncurrently available to the Company. The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, whether as a result\nof new information, future events, or otherwise, except as may be required by\nlaw.\n\nNovaBridge Investor & Media Contacts\n\nInvestors:\nBill Begien, SVP, Investor Relations\n+1-240-745-6330\nbill.begien@novabridge.com \nIR@novabridge.com \n\nMedia Inquiries:\nEric Van Zanten, VP, Communications\n+1-610-529-6219\neric.vanzanten@novabridge.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0ea9f005-c7f7-4272-a3ac-cbf4ea4aef15)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-08T20:05:00.337319987Z","server_sent_at_ms":1791489900337},"received_at":"2026-10-08T20:05:00.441Z","source_url":null},"analysis":{"id":"153211","press_release_id":"164805","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"NovaBridge Biosciences will present expanded safety and efficacy data for givastomig, its CLDN18.2 x 4-1BB bispecific antibody, at the ESMO Congress 2026 in Madrid on October 25.\n\nThe data cover the Phase 1b combination with nivolumab and chemotherapy in first-line HER2-negative, CLDN18.2-positive gastroesophageal adenocarcinoma, and management says findings strengthen confidence as the program advances toward registrational development.\n\nGivastomig holds FDA Fast Track Designation and is now in a global randomized Phase 2 study (NCT07432295); no new clinical results were disclosed in this announcement.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Watch the October 25 ESMO poster (2945P) for expanded givastomig data ahead of registrational development."},"keyFigures":{"drugName":"givastomig (TJ033721 / ABL111)","phaseOfTrial":"Phase 1b (combination with nivolumab and mFOLFOX6); global randomized Phase 2 ongoing (NCT07432295)","customDimensions":{"trialId":"NCT07432295","conference":"ESMO Congress 2026","presentationDate":"October 25, 2026","presentationNumber":"2945P","fastTrackDesignation":true}},"quotedText":"These findings further strengthen our confidence in the program as we advance toward registrational development in first-line metastatic gastroesophageal adenocarcinoma.","namedEntities":{"people":[{"name":"Phillip Dennis, MD, PhD","role":"Chief Medical Officer of NovaBridge"},{"name":"Samuel J. Klempner, MD","role":"Presenter; Associate Professor of Medicine at Massachusetts General Hospital"}],"products":["givastomig (TJ033721 / ABL111)","nivolumab","mFOLFOX6","VIS-101","ragistomig","uliledlimab"],"companies":[{"name":"NovaBridge Biosciences","ticker":"NBP","relationship":"filer"},{"name":"Massachusetts General Hospital","relationship":"presenter institution"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Announcement of upcoming expanded Phase 1b data presentation at ESMO 2026; no new data disclosed yet, but management expresses confidence and notes advancement toward registrational development."},"tickerRelevance":{"others":[],"primary":"NBP"},"globalImportance":22,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap biotech","eventGravity":"conference data announcement, no new results","issuerAuthored":true,"clinicalCatalyst":"ESMO poster Oct 25, 2026"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"NovaBridge Biosciences will present expanded safety and efficacy data for givastomig, its CLDN18.2 x 4-1BB bispecific antibody, at the ESMO Congress 2026 in Madrid on October 25.\n\nThe data cover the Phase 1b combination with nivolumab and chemotherapy in first-line HER2-negative, CLDN18.2-positive gastroesophageal adenocarcinoma, and management says findings strengthen confidence as the program advances toward registrational development.\n\nGivastomig holds FDA Fast Track Designation and is now in a global randomized Phase 2 study (NCT07432295); no new clinical results were disclosed in this announcement.","key_figures":{"drugName":"givastomig (TJ033721 / ABL111)","phaseOfTrial":"Phase 1b (combination with nivolumab and mFOLFOX6); global randomized Phase 2 ongoing (NCT07432295)","customDimensions":{"trialId":"NCT07432295","conference":"ESMO Congress 2026","presentationDate":"October 25, 2026","presentationNumber":"2945P","fastTrackDesignation":true}},"named_entities":{"people":[{"name":"Phillip Dennis, MD, PhD","role":"Chief Medical Officer of NovaBridge"},{"name":"Samuel J. Klempner, MD","role":"Presenter; Associate Professor of Medicine at Massachusetts General Hospital"}],"products":["givastomig (TJ033721 / ABL111)","nivolumab","mFOLFOX6","VIS-101","ragistomig","uliledlimab"],"companies":[{"name":"NovaBridge Biosciences","ticker":"NBP","relationship":"filer"},{"name":"Massachusetts General Hospital","relationship":"presenter institution"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T20:05:10.556Z","global_importance":22,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap biotech","eventGravity":"conference data announcement, no new results","issuerAuthored":true,"clinicalCatalyst":"ESMO poster Oct 25, 2026"}},"durationMs":10058,"modelName":"glm-5.3-flashx"}}